A recent study raises doubts about whether oseltamivir should be promoted as a way to prevent hospitalization in low-risk patients.
1 Nov 2023
Viral load of SARS-CoV-2 doesn't peak until the fourth day of symptoms, one study found, while other research only saw an effect of nirmatrelvir/ritonavir on death and hospitalization among those who were moderately or severely immunocompromised, not in other high-risk groups.
3 Oct 2023
Rebound of both COVID-19 symptoms and viral load was rare in untreated, unvaccinated outpatients, one study showed, while another found similar rates of viral rebound in patients treated with nirmatrelvir-ritonavir, molnupiravir, or neither antiviral.
21 Feb 2023
Internal medicine physicians are already trained to care for complex medical conditions, and HIV is no different, especially as adults age and develop diabetes, heart disease, and other conditions.
1 Nov 2023
Although combination antiviral and antibiotic therapy was associated with a significant reduction in respiratory hospitalization risk within 30 days compared to an antiviral alone in this study, that does not mean the combination should be widely used, the authors noted.
4 Feb 2020
Physicians should focus not only on influenza vaccinations but on treating patients who will get the disease whether they have been vaccinated or not.
1 Oct 2014
High-risk outpatients with acute respiratory illness infrequently prescribed antivirals for influenza, study finds
Factors associated with antiviral treatment were early presentation to care, presence of fever, positive influenza test result, and presentation within the 2013–2014 and 2014–2015 seasons.
31 Oct 2017
Major changes to guidance on hepatitis C virus (HCV) include an emphasis on universal screening, new recommendations for managing incomplete treatment adherence, and expansion of treatment eligibility, among others.
6 Jun 2023
A recent ACP/Annals of Internal Medicine forum on COVID-19 considered the timing of vaccination, outpatient treatment, and pre-exposure prophylaxis.
1 Oct 2022
Two recent studies focused on postacute sequelae of SARS-CoV-2 (PASC), while another assessed the effectiveness of nirmatrelvir-ritonavir and molnupiravir in reducing morbidity and mortality from COVID-19.
6 Jun 2023